The diagnostic value of serum fucosylated fetuin A in hepatitis B virus-related liver diseases

Li, Li; Gu, Xing; Fang, Meng; Ji, Jun Ho; Yi, Chenju; Gao, Chunfang

doi:10.1515/cclm-2015-0307

Cited by 18 publications

(17 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Fortunately, lectins have been considered as an extremely useful tool for glycomic and glycoproteomic study that can be used alone or in conjunction with other methods such as MS and CE because of the wide availability, affinity and relative specificity [93]. Several approaches based on lectins including lectin blot [94,95], lectin histochemistry/cytochemisty [29,96], lectin-antibody sandwich enzyme-linked immunosorbent assay (ELISA) [33,44,97], lectin affinity chromatography [98,99], lectin microarray [100][101][102] and lectin microfluidics [103] have been applied to capture the specific glycan of the glycoproteins [102,[104][105][106], enhancing the understanding of aberrant glycosylation and carcinogenesis, accelerating biomarkers recognition and quantitative detection. The Gao group has investigated the diagnostic and prognostic value of fucosylated fetuin A in HCC patients by AAL-based ELISA [107].…”

Section: Lectin-based Technologiesmentioning

confidence: 99%

Aberrant glycosylation and cancer biomarker discovery: a promising and thorny journey

Wang

Zhu

Lubman

2018

Clinical Chemistry and Laboratory Medicine (CCLM)

Self Cite

136

View full text Add to dashboard Cite

Glycosylation is among the most important post-translational modifications for proteins and is of intrinsic complex character compared with DNAs and naked proteins. Indeed, over 50%–70% of proteins in circulation are glycosylated, and the “sweet attachments” have versatile structural and functional implications. Both the configuration and composition of the attached glycans affect the biological activities of consensus proteins significantly. Glycosylation is generated by complex biosynthetic pathways comprising hundreds of glycosyltransferases, glycosidases, transcriptional factors, transporters and the protein backbone. In addition, lack of direct genetic templates and glyco-specific antibodies such as those commonly used in DNA amplification and protein capture makes research on glycans and glycoproteins even more difficult, thus resulting in sparse knowledge on the pathophysiological implications of glycosylation. Fortunately, cutting-edge technologies have afforded new opportunities and approaches for investigating cancer-related glycosylation. Thus, glycans as well as aberrantly glycosylated protein-based cancer biomarkers have been increasingly recognized. This mini-review highlights the most recent developments in glyco-biomarker studies in an effort to discover clinically relevant cancer biomarkers using advanced analytical methodologies such as mass spectrometry, high-performance liquid chromatographic/ultra-performance liquid chromatography, capillary electrophoresis, and lectin-based technologies. Recent clinical-centered glycobiological studies focused on determining the regulatory mechanisms and the relation with diagnostics, prognostics and even therapeutics are also summarized. These studies indicate that glycomics is a treasure waiting to be mined where the growth of cancer-related glycomics and glycoproteomics is the next great challenge after genomics and proteomics.

show abstract

Section: Lectin-based Technologiesmentioning

confidence: 99%

Aberrant glycosylation and cancer biomarker discovery: a promising and thorny journey

Wang

Zhu

Lubman

2018

Clinical Chemistry and Laboratory Medicine (CCLM)

Self Cite

136

View full text Add to dashboard Cite

show abstract

“…There are two major strategies for Fuc glycoproteins analyses: (1) targeted Fuc proteins measurement by ELISA, western/lectin blot, or mass spectrometry (MS) 6,13,14,16,19,20 and (2) large-scale Fuc glycoproteomes profiling by MS analysis. 8,10,18,21–24 The second approach may be more comprehensive as it facilitates the understanding of underlying mechanisms associated with tumorigenesis and metastasis as well as the discovery of novel potential biomarkers for early clinical diagnosis.…”

mentioning

confidence: 99%

Site-Specific Fucosylation Analysis Identifying Glycoproteins Associated with Aggressive Prostate Cancer Cell Lines Using Tandem Affinity Enrichments of Intact Glycopeptides Followed by Mass Spectrometry

Zhou

Yang

et al. 2017

Anal. Chem.

View full text Add to dashboard Cite

Fucosylation (Fuc) of glycoproteins plays an important role in regulating protein function and has been associated with the development of several cancer types including prostate cancer (Pca). Therefore, the research of Fuc glycoproteins has attracted increasing attention recently in the analytical field. Herein, a strategy based on lectin affinity enrichments of intact glycopeptides followed by mass spectrometry has been established to evaluate the specificities of various Fuc-binding lectins for glycosite-specific Fuc analysis of nonaggressive (NAG) and aggressive (AG) Pca cell lines. The enrichment specificities of Fuc glycopeptides using lectins (LCA, PSA, AAL, LTL, UEA I, and AOL) and MAX extraction cartridges alone, or in tandem, were evaluated. Our results showed that the use of lectin enrichment significantly increased the ratio of fucosylated glycopeptides to total glycopeptides compared to MAX enrichment. Furthermore, tandem use of lectin followed by MAX increased the number of identifications of Fuc glycopeptides compared to using lectin enrichment alone. LCA, PSA, and AOL showed stronger binding capacity than AAL, LTL, and UEA I. Also, LCA and PSA bound specifically to core Fuc, whereas AOL, AAL, and UEA I showed binding to both core Fuc and branch Fuc. The optimized enrichment method with tandem enrichment of LCA followed by MAX (LCA-MAX) was then applied to examine the Fuc glycoproteomes in two NAG and two AG Pca cell lines. In total, 973 intact Fuc glycopeptides were identified and quantified from 252 Fuc proteins by using the tandem-mass-tags (TMT) labeling and nanoliquid chromatography–mass spectrometry (nanoLC–MS/MS) analysis. Further data analysis revealed that 51 Fuc glycopeptides were overexpressed more than 2-fold in AG cell lines compared to NAG cells. The analysis of protein core fucosylation has great potential for aiding our understanding of invasive activity of AG Pca and may lead to the development of diagnostic approaches for AG Pca.

show abstract

“…Most of the biomarker discovery studies have been performed in cohorts of a few 100 patients. The majority of identified markers has so far not been subject of large, external validation studies[ 100 - 103 , 108 ]. Five subsequent steps are to be followed in cancer biomarker discovery.…”

Section: Discussionmentioning

confidence: 99%

“…Based on systems biology approaches, more markers with diagnostic potential in HCC screening settings have recently been identified, including fucosylated fetuin A, inter-alpha-trypsin inhibitor H4, clusterin, endoglin, soluble Axl, latent TGF-bèta binding-protein 2 as well as peroxireduxin 1, 2 and 3. The evidence for clinical utility of these markers remains low due to a lack of sufficiently large cohort studies[ 100 - 108 ].…”

Section: Diagnostic Biomarkers For Hcc: An Overviewmentioning

confidence: 99%

Circulating predictive and diagnostic biomarkers for hepatitis B virus-associated hepatocellular carcinoma

Hees

Michielsen

Vanwolleghem

2016

WJG

View full text Add to dashboard Cite

Chronic hepatitis B virus (HBV) infected patients have an almost 100-fold increased risk to develop hepatocellular carcinoma (HCC). HCC is the fifth most common and third most deadly cancer worldwide. Up to 50% of newly diagnosed HCC cases are attributed to HBV infection. Early detection improves survival and can be achieved through regular screening. Six-monthly abdominal ultrasound, either alone or in combination with alpha-fetoprotein serum levels, has been widely endorsed for this purpose. Both techniques however yield limited diagnostic accuracy, which is not improved when they are combined. Alternative circulating or histological markers to predict or diagnose HCC are therefore urgently needed. Recent advances in systems biology technologies have enabled the identification of several new putative circulating biomarkers. Although results from studies assessing combinations of these biomarkers are promising, evidence for their clinical utility remains low. In addition, most of the studies conducted so far show limitations in design. Attention must be paid for instance to different ethnicities and different etiologies when studying biomarkers for hepatocellular carcinoma. This review provides an overview on the current understandings and recent progress in the field of diagnostic and predictive circulating biomarkers for hepatocellular carcinoma in chronically infected HBV patients and discusses the future prospects.

show abstract

The diagnostic value of serum fucosylated fetuin A in hepatitis B virus-related liver diseases

Abstract: The results indicated that the serum fuc-fetuin A might serve as a potential glycan biomarker for distinguishing LC and HCC from LF, HBV-carriers and healthy controls. Furthermore, the preoperative fuc-fetuin A level could be a useful prognostic biomarker for HCC patients.

Cited by 18 publications

References 30 publications

Aberrant glycosylation and cancer biomarker discovery: a promising and thorny journey

Aberrant glycosylation and cancer biomarker discovery: a promising and thorny journey

Site-Specific Fucosylation Analysis Identifying Glycoproteins Associated with Aggressive Prostate Cancer Cell Lines Using Tandem Affinity Enrichments of Intact Glycopeptides Followed by Mass Spectrometry

Circulating predictive and diagnostic biomarkers for hepatitis B virus-associated hepatocellular carcinoma

Contact Info

Product

Resources

About